Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRain Enhancement Technologies Holdco, Inc. Class A Common Stock

Rain Enhancement Technologies Holdco, Inc. Class A Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.5388 USD -0.01 ( 1.59%)
Last update at 2026-11-04T15:11:00Z
VOLUME
7327
Market Cap
44.38M

Momentum Score

…

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.52
Low
0.55
High
52 Week Price Range
0.82
Low
14.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) describes itself as a developer of precipitation-enhancement and weather-modification technologies for water resource and agricultural applications. Long-term growth may be driven by demand for climate adaptation and water-security solutions, which could appeal to investors seeking specialized environmental technology exposure.

Principal risks include regulatory and permitting uncertainty, limited commercial track record and revenue predictability, dependence on variable weather outcomes, and execution and funding risks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.55
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-97.04%
Net Debt
-61.68M
ROCE
-68.20%
Diluted EPS TTM
-2.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -75.72M -51.39M -21.08M -10.90M
Net income -75.72M -51.39M -19.20M -10.68M
Selling general administrative 15.74M 10.74M 3.59M 3.54M
Reconciled depreciation 0.08M 0.07M 0.05M 0.03M
Ebit -77.22M -51.51M -18.96M -10.83M
Ebitda -77.14M -51.39M -20.90M -10.84M
Depreciation and amortization 0.08M 0.12M -1.94M -0.01M
Non operating income net other 1.42M 0.12M - -
Operating income -77.14M -51.51M -18.96M -10.83M
Other operating expenses 77.14M 51.51M 18.96M 10.83M
Interest expense 1.50M 0.07M 0.14M 0.03M
Tax provision 0.00M 0.00M - -
Interest income 1.42M 0.12M 0.03M 0.21M
Net interest income 1.42M 0.12M -0.10M 0.18M
Income tax expense 0.00M 0.00M -1.89M -0.22M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 77.14M 51.51M 18.96M 10.83M
Total other income expense net 1.42M 0.12M -2.12M -0.07M
Net income from continuing ops -75.72M -51.39M -21.08M -10.90M
Net income applicable to common shares -75.72M -51.39M -21.08M -10.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 135.18M 147.14M 61.08M 7.39M
Other current assets 0.15M 0.20M 0.13M 0.11M
Total liab 22.14M 16.64M 98.50M 24.64M
Total stockholder equity 113.04M 130.50M -37.42M -17.25M
Deferred long term liab - - 0.39M -
Other current liab 14.66M 10.04M 2.46M 0.83M
Common stock 0.04M 0.03M 0.00M 0.00M
Capital stock 0.04M 0.03M 0.00M 0.00M
Retained earnings -165.69M -89.96M -38.57M -17.49M
Other liab 0.07M 0.07M 0.07M 0.10M
Other assets 1.20M 0.44M 1.01M 0.43M
Cash 61.95M 24.78M 58.86M 5.79M
Total current liabilities 21.97M 16.32M 3.42M 1.22M
Net debt -61.68M -24.37M -58.41M -2.48M
Short term debt 0.16M 0.16M 0.14M 0.14M
Short long term debt total 0.28M 0.41M 0.45M 3.31M
Other stockholder equity 278.85M 73.39M 1.15M 0.24M
Property plant equipment 0.09M 0.17M 0.55M 0.69M
Total current assets 133.63M 146.15M 59.52M 6.27M
Net tangible assets 113.04M 130.50M -37.42M -17.25M
Short term investments 68.50M 115.44M - -
Net receivables 0.57M 0.45M 0.11M -
Long term debt - - - 2.75M
Inventory 2.45M 5.27M - -
Accounts payable 7.15M 6.11M 0.82M 0.26M
Accumulated other comprehensive income -0.17M -0.09M -0.09M -0.03M
Common stock total equity 0.04M 0.03M 0.00M 0.00M
Retained earnings total equity -165.69M -89.96M - -
Non currrent assets other 1.20M 0.44M 1.01M 0.43M
Non current assets total 1.55M 0.99M 1.55M 1.12M
Capital lease obligations 0.28M 0.41M 0.45M 0.56M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 47.20M -115.61M -5.19M -0.14M
Change to liabilities 2.76M 7.43M 0.56M -0.25M
Total cashflows from investing activities 47.19M -118.23M -5.19M -0.14M
Net borrowings - - 6.43M 6.43M
Total cash from financing activities 53.18M 121.61M 69.49M 2.50M
Change to operating activities 7.90M -0.10M 1.05M -0.58M
Net income -75.72M -51.39M -21.08M -10.90M
Change in cash 37.17M -34.08M 53.07M -8.83M
Begin period cash flow 24.78M 58.86M 5.79M 14.62M
End period cash flow 61.95M 24.78M 58.86M 5.79M
Total cash from operating activities -63.20M -37.46M -11.23M -11.18M
Issuance of capital stock 56.65M 133.37M 63.17M 0.00M
Depreciation 0.08M 0.07M 0.05M 0.03M
Other cashflows from investing activities - -2.50M - -
Sale purchase of stock 0.61M 121.61M - -
Other cashflows from financing activities -4.08M -11.75M 69.49M -0.14M
Change to netincome 4.85M 8.59M 8.19M 0.52M
Capital expenditures 0.01M 2.63M 5.19M 0.14M
Cash flows other operating 5.17M -2.24M - -
Cash and cash equivalents changes 37.17M -34.08M - -
Change in working capital 8.93M 5.19M 1.61M -0.83M
Stock based compensation 4.86M 3.09M 0.86M 0.24M
Other non cash items -1.34M 5.50M 7.33M 0.28M
Free cash flow -63.21M -40.09M -16.42M -11.33M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RAIN
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock		 -0.01
1.59%		 0.54 - - - 0.65 0.44
NVO
Novo Nordisk A/S		 2.50
6.23%		 42.70 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.96
0.18%		 531.72 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -6.27
0.64%		 967.09 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Rain Enhancement Technologies Holdco, Inc. Class A Common Stock

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

8000 Jarvis Avenue, Newark, CA, United States, 94560

510 953 5559

https://www.rainthera.com

63

Name Title Year Born
Mr. Avanish Vellanki M.B.A. Co-Founder, CEO & Chairman 1975
Dr. Robert C. Doebele M.D., Ph.D. Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer 1972
Dr. Richard P. Bryce Exec. VP & Chief Medical Officer 1957
Mr. Nelson D. Cabatuan Sr. VP of Fin. & Admin. 1978
Ms. Theresa O'Connell M.S. Director of Corp. Devel. & Operations NA
Ms. Vijaya Tirunagaru Ph.D. Sr. VP & Head of Research NA
Mr. Lucio Tozzi Sr. VP of Clinical Operations 1964
Ms. Buenaflor Nicolas M.P.H. VP, Head Global Drug Safety & Pharmacovigilance NA
Dr. Nora Ku M.D. MD & VP of Clinical Devel. NA
Dr. Mehdi Paborji Ph.D. Sr. VP of Technical Operations 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…